Evidence for a Matrix Metalloproteinase Induction/Activation System in Arterial Vasculature and Decreased Synthesis and Activity in Diabetes
- 1 October 2002
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 51 (10) , 3063-3068
- https://doi.org/10.2337/diabetes.51.10.3063
Abstract
Pathological remodeling characterized by extracellular matrix (ECM) deposition contributes to the diabetic vascular complications. Matrix metalloproteinases (MMPs) regulate ECM turnover. However, the expression profile of the MMP system in diabetic human tissue remains unknown. The objectives of this study were 1) to identify a local MMP induction/activation system that exists in arterial vasculature and 2) to determine how the MMP system may be altered in diabetes. Internal mammary artery specimens were obtained from patients who did (n = 14) and did not (n = 14) have diabetes and were undergoing coronary artery bypass grafting surgery. ECM inducer protein (EMMPRIN); membrane-type MMP (MT-MMP); and MMP-1, -2, and -9 were quantified by immunoblotting and densitometric scanning (pixels). Pro-MMP-1 and MMP-2 levels were decreased from 952 ± 120 and 1,081 ± 508 pixels, respectively, in nondiabetic tissue to 398 ± 62 and 249 ± 42 pixels in the diabetic tissue (P < 0.05). Both EMMPRIN and MT-MMP expression and total MMP activity were decreased by twofold in diabetic patients (P < 0.05). These results demonstrated for the first time that an MMP induction and activation system exists in human arterial vasculature and that it is downregulated in diabetes. Decreased MMP activity may contribute to increased collagen deposition and pathological remodeling in diabetes.Keywords
This publication has 27 references indexed in Scilit:
- Cardiac remodeling after long term norepinephrine treatment in ratsCardiovascular Research, 2001
- High Glucose Decreases Matrix Metalloproteinase-2 Activity in Rat Mesangial Cells via Transforming Growth Factor-β1Nephron Experimental Nephrology, 2001
- Diabetes Mellitus Enhances Vascular Matrix Metalloproteinase ActivityCirculation Research, 2001
- Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathyBritish Journal of Ophthalmology, 2000
- Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension.International Journal of Cardiology, 2000
- Binding of Active (57 kDa) Membrane Type 1-Matrix Metalloproteinase (MT1-MMP) to Tissue Inhibitor of Metalloproteinase (TIMP)-2 Regulates MT1-MMP Processing and Pro-MMP-2 ActivationJournal of Biological Chemistry, 2000
- Cellular Mechanisms of Diabetic Vascular HypertrophyMicrovascular Research, 1999
- Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products.Journal of Clinical Investigation, 1997
- Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability.Journal of Clinical Investigation, 1996
- Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.Journal of Clinical Investigation, 1994